Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$326K Buy
6,764
+242
+4% +$12.4K 0.08% 209
2026
Q2
$342K Buy
6,522
+630
+11% +$33.3K 0.09% 204
2026
Q1
$325K Buy
5,892
+859
+17% +$46.5K 0.1% 198
2025
Q4
$247K Buy
+5,033
New +$235K 0.07% 214

Other funds holding GSK

Focused Alpha's GSK Position: Q3 2026 in Review

Focused Alpha increased its GSK (GSK) stake by 3.7% in Q3 2026, buying an estimated $12.4K and bringing the position to 6,764 shares worth $326K. The position accounts for 0.08% of the portfolio, ranked #209.

Focused Alpha first reported a position in GSK in Q4 2025 and has held it in 4 quarters since. The position peaked at $342K in Q2 2026. 854 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

  • Focused Alpha held 6,764 shares of GSK worth $326K as of Q3 2026.
  • Focused Alpha bought 242 GSK shares in Q3 2026, an estimated $12.4K.
  • GSK made up 0.08% of Focused Alpha's portfolio in Q3 2026, its #209 holding.
  • Focused Alpha first reported a position in GSK in Q4 2025 and has held it in 4 quarters since.
  • Focused Alpha's GSK position peaked at $342K in Q2 2026.
  • 854 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Focused Alpha's 13F filing for Q3 2026, filed 20 Oct 2026.